Abstract
Recent studies have clarified the novel mediators and neuronal pathways involved in itch transmission, which might result in introduction of new therapies for management of pruritus in the near future. Involvement of peroxisome proliferator-activated receptor (PPAR) signaling in the pathogenesis of skin diseases was suggested in recent experiments. PPAR-γ agonists, thiazolidinediones, which are used in the treatment of diabetes mellitus, have been recently shown to diminish pruritus not only in animal models, but also in patients suffering from psoriasis; nevertheless, the role of PPAR-γ receptors in the pruritus is not well understood. In this perspective, a brief overview on the function of PPAR signaling in the pathogenesis of skin disorders as well as the involvement of PPAR-γ impact on pruritus is argued. Detecting the relationship between PPAR-γ signaling and itching could lead to the emergence of novel therapies for management of pruritus in a wide range of dermatological and systemic disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
